Cardinal James, Slade Austen, McFarland Mary, Keihani Sorena, Hotaling James N, Myers Jeremy B
Division of Urology, Department of Surgery, University of Utah, 30 North 1900 East, Salt Lake City, UT, 84132, USA.
Spencer S. Eccles Health Sciences Library, University of Utah, Salt Lake City, UT, USA.
Curr Urol Rep. 2018 Apr 13;19(6):38. doi: 10.1007/s11934-018-0790-3.
To critically review and summarize existing literature assessing the effectiveness of hyperbaric oxygen therapy (HBOT) for the treatment of radiation-induced urologic injury.
Though 5 of the included 13 studies were published in the last 2-3 years, the only randomized controlled study was performed in 2012. Recent studies have confirmed the safety and efficacy of HBOT as well as identified risk factors for success vs. failure of HBOT for hemorrhagic radiation cystitis (HRC). Of the 602 patients that received HBOT for HRC, 84% had a partial or complete resolution. In the 7 studies that utilized RTOG/EORTC, 75% of patients saw an improvement in hematuria of at least one grade (out of possible 5 total). Of the 499 patients with documented follow-up, 14% experienced recurrence, with a median time to recurrence of 10 months (6 to 16.5 months).
批判性地回顾和总结现有文献，评估高压氧治疗（HBOT）对放射性泌尿损伤的治疗效果。
尽管纳入的13项研究中有5项是在过去2至3年发表的，但唯一的随机对照研究是在2012年进行的。近期研究证实了HBOT的安全性和有效性，并确定了HBOT治疗出血性放射性膀胱炎（HRC）成功与失败的风险因素。在接受HBOT治疗HRC的602例患者中，84%有部分或完全缓解。在7项采用RTOG/EORTC标准的研究中，75%的患者血尿至少改善了1级（共5级）。在有记录随访的499例患者中，14%出现复发，复发的中位时间为10个月（6至16.5个月）。
